What have we learnt from Vioxx?

被引：167

作者：

Krumholz, Harlan

Ross, Joseph S.

Presler, Amos H.

Egilman, David S.

机构：

[1] Yale Univ, Sch Med, Dept Med, New Haven, CT 06520 USA

[2] Mt Sinai Sch Med, Dept Geriatr & Adult Dev, New York, NY USA

[3] Never Again Consulting, Attleboro, MA USA

[4] Brown Univ, Dept Biomed Community Hlth, Providence, RI 02912 USA

来源：

BMJ-BRITISH MEDICAL JOURNAL | 2007年 / 334卷 / 7585期

关键词：

D O I：

10.1136/bmj.39024.487720.68

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

In October UK patients who had cardiovascular events while taking rofecoxib lost the right to fight Merck in the US for compensation. But researchers and journals can still benefit from this case if they learn from the mistakes, write Harlan Krumholz and colleagues.

引用

页码：120 / 123

页数：8

共 59 条

[21]

*FOOD DRUG ADM, 1999, HFD550 FOOD DRUG ADM

[22]

*FOOD DRUG ADM, 2001, 21042 NDA FDA ADV CO

[23]

FRIES JF, 2001, COMMUNICATION 0109

[24]

Furberg CD, 2006, NEW ENGL J MED, V355, P204

[25] Clinical implications of drug interactions with coxibs [J].

Garnett, WR .

PHARMACOTHERAPY, 2001, 21 (10) :1223-1232

[26] Pain management in older adults: Prevention and treatment [J].

Gloth, FM .

JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2001, 49 (02) :188-199

[27]

HAWTHORNE F, 2003, MERCK DRUGGEMAUT INS

[28]

Hochberg MC, 2002, AM J MANAG CARE, V8, pS502

[29]

*IMS HLTH, 2004, NAT PRESCR AUD PLUS

[30] Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib [J].

Konstam, MA ;

Weir, MR ;

Reicin, A ;

Shapiro, D ;

Sperling, RS ;

Barr, E ;

Gertz, BJ .

CIRCULATION, 2001, 104 (19) :2280-2288

← 1 2 3 4 5 6 →